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Epithelial ovarian cancer (EOC) continues to represent one of the most lethal conditions in women in the western countries. With
the shifting of childbearing towards higher age, EOC increasingly aﬀects women with active childbearing wish, resulting in major
impacts on treatment management. Next to the optimal therapeutic treatment strategies, gynecologic oncologists are being asked
to incorporate into their decision-making processes the patients’ wish for fertility preserving alternatives ideally without compro-
mising oncologic safety. Nowadays, fertility-sparing surgery represents an eﬀective alternative to conventional radical cytoreduc-
tion in younger women with early stages of the disease. As such, this paper considers indications for fertility sparing surgery in
EOC, reﬂects on outcomes from the oncologic and reproductive data of the largest and most relevant series outcomes data, report-
ing on fertility sparing techniques in EOC, reviews medicamentous eﬀorts to prevent chemotherapy induced gonadotoxicity, and
discusses future aspects in the gynecologic cancer management.
1.Introduction
Epithelial ovarian cancer (EOC) continues to represent a
lethal condition which commonly aﬀects women in a multi-
focal and peritoneal metastasized fashion. Attributed to a
special tumor biology and large heterogeneity, clinical out-
comes in EOC vary broadly and although signiﬁcantly asso-
ciated with an adequate systemic and operative treatment,
theyoftendetachthemselvesfromthesecommonandknown
inﬂuential factors and follow not yet fully understood tumor
biology patterns [1].
With the constant shifting of childbearing age towards
higher ages, the increasing incidence of EOC in women with
active childbearing potential constitutes a therapeutic di-
lemma [2]. Both patients and treating physicians are being
encountered with the abrupt loss of childbearing potential
due to the malignant disease, while alternatives are being
sought that try to preserve a last hope of fertility within the
antitumor treatment [3].
Even though radical surgery with the primary objective
of maximal tumor reduction is currently the established cor-
nerstone in the management of advanced EOC [4], fertility-
sparingtechniquesarebeingincreasinglyincorporatedinthe
therapeutic strategies in early or not bulky forms of the dis-
ease. Equivalent to the nowadays established organ-preserv-
ing techniques in borderline ovarian tumors, also in early
EOC, strategies like preservation of the contralateral ovary
and uterus or even in highly specialized cases peritonectomy
of the pelvis and uterus serosa to avoid the need of hysterec-
tomy are being recruited [5, 6]. The subsequent systemic
chemotherapy within “fertility protecting” programs where
chemotherapy is being applied under the concomitant ovar-
ian protection via substances like GnRH analog a addition-
ally induce fertility-sparing treatment and oﬀer the aﬀected
woman a hope for conception after completion of the anti-
cancer treatment.
Nevertheless, the inevitable question arises, whether fer-
tility-sparing surgery (FSS) for EOC harbors life-threatening2 Obstetrics and Gynecology International
risks, which compromise patient’s survival and set any
chance for a normal family life into the background due to
early and potentially chemotherapy-resistant relapse.
Since no randomized trials exist or will ever exist to pro-
spectively evaluate and answer this question, our experience
is limited to scattered, retrospective cases series. The aim of
this paper is to provide an overview of the most signiﬁcant
hitherto reports and discuss future perspectives.
2. CurrentIndicationsfor FSS inEOC
FSSforovarianneoplasmshavebeentraditionallyadoptedin
early-stage malignant ovarian germ cell tumors and in ovar-
ian sex cord-stromal tumors such as granulosa-cell tumors,
Sertoli-Leydigcelltumors,ovariandysgerminomas,aswellas
inborderlinetumorsoftheovarywithexcellentreproductive
outcomes without compromising oncologic safety [7–9].
Gold standard remains however hereby an adequate opera-
tive staging in order to unmask occult advanced disease with
therapeutic consequences and impact on overall prognosis.
For invasive EOC data are much more constricted and
limited to retrospective, nonrandomised series referring
mainly to patients with low-grade stage IA tumors with fa-
vorable histology, while data regarding higher stages of the
disease or unfavorable constellation of histologic character-
istics are rather conﬂicting [6, 10–12]. Overall, in selecting
optimal candidates for FSS, the amount of evidence has been
too small to accurately estimate the risk of leaving a micro-
scopic tumor in the contralateral ovary [13], especially in
high-grade disease with positive peritoneal cytology.
Accordingtothe2007guidelinesoftheAmericanCollege
of Obstetrics and Gynecology (ACOG), fertility-sparing sur-
gery for reproductive-age patients with invasive EOC is rec-
ommended for highly or moderately diﬀerentiated stage IA
disease with non-clear-cell histology [14]. In an equivalent
manner,theEuropeanSocietyforMedicalOncology(ESMO)
referringin2008tofertility-sparingtechniquesinEOCiden-
tiﬁed patients with unilateral stage I tumor without dense
adhesions showing favorable histology (i.e., high or moder-
ate diﬀerentiated, non-clear-cell histology) as being the op-
timal candidates for this procedure [15]. However, the num-
ber of published studies concerning fertility-sparing surgery
in young EOC patients is rather limited and the evaluated
patient’s samples too small to allow unanimous consensus
regarding the deﬁnition of the selection criteria of the opti-
mal candidate for fertility-sparing surgery in stage I EOC.
That leads to a broad variety of national guidelines regarding
FSS worldwide, especially in respect to Ic (iatrogenic versus
not) and/or poorly diﬀerentiated disease and to clear cell
histologic subtype [16]. Moreover, under additional consid-
eration of the relatively recently emerging dualistic model
theory of EOC pathogenesis, which divides EOC in type I
and type II disease [17], patients selection for FSS could
theoretically be performed under this perspective and hence
indicated for early-stage, type I tumors, even though there is
currently no evidence that would support such an approach.
Open questions remain if there should be diﬀerentiation
between iatrogenic Ic disease due to intraoperative tumor
r u p t u r ev e r s u sI cd u et ot u m o ro no v a r i a ns u r f a c eo rm a -
lignant cells in peritoneal cytology, whether patients with
G3 tumors with no evidence of further metastatic disease in
adequate staging are eligible of FSS and whether nonserous
or non-endometrioid histologic subtypes should be a priori
excluded from any organ-preserving technique.
3. Oncologic Outcomes after FSS in EOC
Data from the largest report series in the literature concern-
ing oncologic outcome after FSS in EOC are summarized in
Table 1. Zanetta et al. published in the year 1997 one of the
ﬁrst reports regarding this issue and was the ﬁrst to sys-
tematically show that fertility-sparing surgery is a safe treat-
ment option for early-stage patients with acceptable onco-
logic safety proﬁle [12]. Various case series or case reports
followed since then with a large peak in the last two years of
reports mostly originating from Japan. Satoh et al. attempted
fortheﬁrsttimein2010tosystematicallydetermineselection
criteria for fertility-sparing surgery in stage I EOC on the
basis of clinical outcomes of more than 200 stage I EOC pa-
tients who underwent fertility-sparing surgery [16]. A re-
l a p s er a t ea sh i g ha s8 . 5 %w a sr e p o r t e dw i t h2 7 %o ft h e
relapsed patients presenting recurrence exclusively in the re-
maining ovary without any distant or peritoneal metastases.
Hence, the authors identiﬁed stage Ia EOC patients with
favorable histology, that is, mucinous, serous, endometrioid,
or mixed histology and grade 1 or 2, as the optimal can-
didates to safely undergo fertility-sparing surgery even with-
out an obligatory subsequent platinum-based adjuvant
chemotherapy. In case of stage Ia disease with clear cell his-
tology or stage Ic with unilateral ovarian involvement and
favorable histology, authors emphasized the need of a com-
plete surgicalstaging and an adjuvant platinum-based chem-
otherapy, since the 5-year recurrent-free survival rate of the
ﬁfteen evaluated patients with stage Ic clear cell carcinoma
was with 66.0% comparably high, while the ﬁfteen patients
withstageIaclearcellcarcinomashowednoevidenceoflocal
or distant recurrence. Concerning patients with unfavorable
constellation of histological tumor type, that is, stage Ia/G3
disease or stage Ic with clear cell or G3 histology, the authors
recommended their exclusion from any fertility-sparing sur-
gical approach [16].
When collectively evaluating most published results so
far, mean relapse rates are estimated to be around 10%, even
in patient’s cohorts which included also Ic stage disease [12,
13, 18, 20–23]. Nevertheless, when accurately examining the
characteristics of the patients who suﬀered from relapse,
they belonged mainly to the subgroup with Ic and/or G3
tumors. Interestingly in many studies no diﬀerentiation oc-
curs between Ic due to iatrogenic cyst rupture versus Ic due
to malignant cells in the douglas cytology or surface involve-
ment. Kajiyama et al. [23] assessed survival after FSS sepa-
rately for these two patients’ subgroups, that is, iatrogenic
versus tumorbiologic Ic. He came to the conclusion that
progression and overall survival of the patients with stage
Ic (surface involvement/positive cytology) were signiﬁcantly































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.4 Obstetrics and Gynecology International
this was not the case when comparing survival rates of pa-
tients after FSS with Ia versus iatrogenic Ic disease, that is,
after intraoperative tumor rupture.
In the study of Zanetta et al., none of the women under-
going bilateral oophorectomy had microscopic foci of cancer
in the normal-looking contralateral ovary. The rate of bilat-
erality is congruent with the previous observations of other
authors who reported an extremely low rate of contralateral
involvement for mucinous tumours [12].
In two very recent studies originating also from the same
authorsgroupbyKajiyamaetal.,theauthorsassessedthefea-
sibility of fertility-sparing surgery in patients with clear cell
or mucinous carcinoma of the ovary, two histological types
which have been associated in various reports with a rather
lessfavorableprognosis[16,22].Inbothanalysestheauthors
concluded that FSS in presence of these two histological sub-
types was not necessarily associated with a poorer prognosis
than after radical surgery and hence feasible. Data are shown
in Table 1. This can be possibly attributed to the fact that the
negative impact of unfavorable histology on survival has
mainly been established for advanced-stage disease III and
IV [24, 25]. Underlying theories are mainly based on an in-
creased chemotherapy resistance to the conventional carbo-
platin and paclitaxel regimens of mainly mucinous cancers
resulting in emerging attempts to treat these types similar
to intestinal cancers with oxaliplatin and capecitabine ±
bevacizumab within randomized trials [24]. In early stage Ia,
however, no adjuvant treatment is necessary, with complete
resection and adequate staging consisting a suﬃcient treat-
ment plan.
When attempting to identify a recurring proﬁle of the
patients who relapsed after FSS, then no speciﬁc pattern can
be identiﬁed, since in various series also Ia patients tend to
recur, whereby here one has to consider the possibility of
occult more advanced disease after inadequate staging. One
of the major limitations of the existing studies is that not
all of the cases underwent an obligatory systematic lymphad-
enectomy, in which case there might occur an up-staging
of some patients [10, 16]. Reported death rates are ranging
between 2 and 15%.
4. ReproductiveOutcomes after
Fertility-SparingSurgeryinEOC
The issue of impaired fertility in young cancer survivors
representsatherapeuticdilemmaforbothtreatingphysicians
andaﬀectedpatients.Systemicandoperativeoncologictreat-
ments consistently compromise the ovarian function, often
resulting in infertility and premature menopause [26–28].
Data regarding reproductive outcome after FSS in EOC
are summarized in Table 2. Literature data concerning the
rate of women with successful conception after FSS accounts
approximately 30% of all patients however, if one takes into
consideration only the women with childbearing wish who
actively tried to conceive, then rates of successful conception
are substantially higher and range from 66% to 100%, indi-
cating that no relevant reproductive impairment exists after
FSS. Also, where reported, only the minority of patients
required assisted reproductive techniques for a successful
conception and pregnancy [3, 10–12, 16, 18, 29].
When evaluating the incidence of spontaneous abor-
tions,thenratesrangebetween11%and33%.Noevidenceis
however given regarding details about the gestational week,
the onset of symptoms, and whether there was a habitual
recurring modus, so that no conclusions can be extracted
about the cause of the abortions and their pathophysiology.
In the recent evaluation by Satoh et al. [16], there are
even details given regarding the restoration of the menstrual
cycle after completion of oncologic treatment. A hundred
and eighty two patients (96.8%) of the overall 188 who gave
information on their menstruation had almost the same
cycle of menstruation as before treatment. However, six
(5.0%) of the 121 patients who received platinum-based
chemotherapy presented a persistent secondary amenorrhea
up to 224 months after completion of 4–6 cycles of systemic
chemotherapy. Details about the reproductive outcome of
this population are given in Table 2. Five (9.1%) of the 55
patients who successfully conceived have been stated to re-
ceive an infertility treatment before pregnancy. Interestingly,
the authors report four (9.4%) of the 53 patients who gave
birth to children having underwent completion surgery after
childbearing, consisting of hysterectomy and contralateral
salpingo-oophorectomy.
Wherever reported, none of the patients who successfully
conceived and gave birth presented any relevant, cancer-re-
lated clinical problems during the perinatal period. Also no
higher rates of congenital malformations or abnormal fetal
outcomes have been reported in the current literature [11,
16, 32].
5. Hormonal Support Options for
OvarianProtectionin
Chemotherapy-Induced Gonadotoxicity
It is well known that the number of oocytes decreases as a
normal process from the fetal life up to menopause. At 20
weeks of gestation, female infants have about six to seven
million oocytes, newborns only one to two million, and
women at the age of 37 have only about 25,000 oocytes left.
Chemotherapeutic agents, which act cytotoxic by interrupt-
ing the normal cell cycle and inducing apoptosis do also
negatively aﬀect the highly endocrine-active ovarian tissue.
Cisplatinanditsanalogues,thatis,agentswhichplayahighly
signiﬁcant role in the management of ovarian cancer, have
been proven to present a risk factor for ovarian failure by
an estimated odds ratio as high as 1.77 [28]. In order to
decrease chemotherapy-induced gonadotoxicity on young
women after FSS, hormonal protection is being recruited to
force the ovarian tissue by pituitary downregulation to enter
into a state of inactivity and so to make it less susceptible to
cytotoxic agents. Various agents have been applied such as
GnRH agonists or antagonists, oral contraceptives, or even
in a newly setting the selective estradiol receptor tamoxifen.
The protective eﬀect of GnRHa against chemotherapy-in-
duced gonadotoxicity is still under debate [33]. The rea-













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.6 Obstetrics and Gynecology International
randomized studies to conﬁrm and establish the protective
eﬀect of such agents. In a recent phase II study by the Ger-
man Hodgkin Study Group, young women with advanced-
stage Hodgkin lymphoma were randomly assigned either
to receive daily OC or monthly GnRH-a during escalated
combinationtherapywithbleomycin,etoposide,adriamycin,
cyclophosphamide, vincristine, procarbazine, and pred-
nisone (BEACOPPesc). The trial had to close prematurely
after an interim analysis which showed that in both arms the
ovarian follicle preservation rate was 0% with a 95% con-
ﬁdence interval ranging between 0% and 12% [34]. To dem-
onstrate the protective eﬀect of the GnRH analogue triptore-
lin, on chemotherapy-induced ovarian gonadotoxicity, Tan
et al. applied diﬀerent doses of triptorelin in combination
with the alkylating agent busulfan in sexually mature, virgin,
female mice. Results have demonstrated a dose-dependent
protective eﬀect against gonadotoxic chemotherapy of a
GnRH analogue on ovarian reserve, thus suggesting a novel
application of GnRH analogues in fertility preservation [35].
Almost all clinical studies assessing the protective eﬀect of
GnRHagentshavebeenconductedinpatientswithhaemato-
logic malignancies, breast cancer, or even nonmalignant dis-
eases which however require a cytotoxic treatment like lupus
erythematodes [36]. Reviewing of all published studies using
GnRH-aororalcontraceptives,dataclearlydemonstratethat
they are too limited to provide conclusive statistical evidence
concerning the reduction of premature ovarian failure, even
though most studies analyzing the eﬀect of hormonal pro-
tectionduringchemotherapyhaveshownareductionofPOF
in patients receiving GnRH-a or OC during systemic chemo-
therapy [36]. Recently, also the combination of GnRH antag-
onist and analogue has been recruited to reduce time for
pituitary downregulation before chemotherapy and to avoid
delayed cancer treatment [33]. Even though there are no suf-
ﬁcient data to support this strategy to date, this combination
approach mainly plays a role in haematologic malignancies
where treatment has to be initiated within days; in the case
of completely staged early EOC, a delay of days or 1-2 weeks
does not have a tremendous impact on survival.
6.FuturePerspectives
The possibility of reproductive dysfunction as a consequence
of cancer treatment has an established negative impact on
the quality of life of cancer survivors [37]. The merged role
of the treating physician as both life-save and protector-of-
futurefertilityhasmadetheﬁeldofoncofertilityasubstantial
part of gynecologic oncology nowadays. Since prospectively
designed, randomized trials to evaluate safety of FSS are
neither possible nor ethical maintainable, our experience in
outcomes after FSS mainly originates from retrospective case
series. The gynecologic oncologist is in a unique position to
provide young cancer patients with up-to-date fertility pres-
ervation information and fertility-sparing surgical alterna-
tives [37]. However, even after FSS, many young patients fail
to fulﬁll their childbearing wish, due to various reasons, such
as early relapse in the remaining ovarian tissue or due to
diminished ovarian reserve. Here additional techniques like
cryopreservation of ovarian tissue, oocytes, or even embryos
are called to oﬀer an additional safety option to young wom-
en. A considerable pitfall however in this approach is the
potential risk that the cryopreserved ovarian tissue might
harbor malignant cells that could induce disease recurrence.
Furthermore, in case of cryopreservation of ovarian tissue
alone, described rates of successful pregnancies are low. Fu-
ture perspectives lie hence in further broadening and opti-
mizing this option by improving eﬃcacy through maximal
exploiting of the stored ovarian tissue and increasing onco-
logic safety. There are novel studies which examine the pos-
sible presence of malignant cells in ovarian cortex from pa-
tients with ovarian tumors by xenografting of the ovarian
tissue into severe combined immunodeﬁciency mice. The
group around Lotz et al. could recently show that none of
these mice presented symptoms of reintroduced malignancy
after xenografting of the ovarian tissue of patients with
malignant ovarian tumors. Moreover, microscopic and im-
munohistochemical evaluation of the grafts did not raise any
suspicion of residual malignant disease [38]. Xenografting in
the murine back muscle is being currently further explored
as a method for human ovarian tissue transplantation [39].
As a distant dream appears, also the possibility of isolating
healthy ovarian tissue or oocytes of bilateral tumor aﬀected
ovaries, where an ovarian preserving approach appears high-
ly hazardous.
7. Conclusion
After thorough insight of the current literature, FSS in early-
stage EOC appears an absolutely viable and safe option for
women younger than 40 years who wish to preserve their
childbearing potential after careful consideration of histo-
logic subtypes. The optimal indication is referring to stage Ia
G1/G2 disease, as well as stage Ic with favorable, that is, non-
clear-cell histology. Here there has to be diﬀerentiated be-
tween iatrogenic—due to intraoperative tumor rupture—
versus biologic Ic disease—due to surface involvement or
positive Douglas cytology—since the latter is associated with
less favorable outcomes after FSS. In case of stage Ic disease
and clear cell histology, there is increasing evidence of a
poorer relapse-free survival compared to non-clear-cell his-
tology. For that reason a fertility-sparing approach in this
specialpatientscollectiveshouldbeindicatedonlyafterthor-
ough discussion and informed consent of the aﬀected pa-
tients with careful balancing of the risks and beneﬁts. In any
case, the treating gynecologic oncologist should be fully
aware of his double role in treating the malignant disease as
wellasinprovidingoncofertilitycaretoyoungEOCpatients,
by considering oﬀering fertility-sparing alternatives when
allowed so by tumor stage and histologic diﬀerentiation.
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